Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IXXLN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
YC1663
|
|||||
| Synonyms |
Ab-MC-MMAF-VC-PAB-DMEDA-PEG (N3)-SN38
Click to Show/Hide
|
|||||
| Organization |
Shanghai Wishing Biotechnology Co ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
J591
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Ab-MC-MMAF-VC-PAB-DMEDA-PEG (N3)-SN38 Linker
|
Linker Info | ||||
| Combination Type |
MC-MMAF-VC-PAB-DMEDA-PEG (N3)-SN38
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 9.269 ng/mL | Positive PSMA expression (PSMA+++/++) | ||
| Method Description |
ADCs (10x the final top concentration) was tested in LNCap cells for 3 days.
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 9.269 ng/mL | Positive PSMA expression (PSMA+++/++) | ||
| Method Description |
ADCs (10x the final top concentration) was tested in C4-2B cells for 3 days.
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||